Sun Pharmaceutical Industries is currently trading at Rs. 674.70, down by 0.85 points or 0.13% from its previous closing of Rs. 675.55 on the BSE.
The scrip opened at Rs. 679.95 and has touched a high and low of Rs. 679.95 and Rs. 671.20 respectively. So far 1,03,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 898.00 on 23-Feb-2016 and a 52 week low of Rs. 572.40 on 09-Nov-2016.
Last one week high and low of the scrip stood at Rs. 725.20 and Rs. 660.00 respectively. The current market cap of the company is Rs. 1,61,922.00 crore.
The promoters holding in the company stood at 54.97%, while Institutions and Non-Institutions held 33.34% and 11.68% respectively.
Sun Pharmaceutical Industries’ Halol facility in Gujarat has inspected by the US Food and Drug Administration (USFDA) from November 17, 2016 to December 1, 2016. The company has been issued a Form 483, citing nine inspectional observations. None of those observations were characterized by the USFDA as repeat observations. The company is preparing its responses to the observations, which will be submitted to USFDA within 15 business days of receipt of the Form-483. The company intends to implement promptly any corrective actions and improvements that may be necessary as a result of the observations and to continue to work cooperatively with USFDA.
Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.40 |
| Dr. Reddys Lab | 1279.70 |
| Cipla | 1304.70 |
| Zydus Lifesciences | 956.65 |
| Lupin | 2245.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: